Academics & Research

Immunology, Inflammation, & Infectious Disease (3i) Initiative

Funding Opportunities

Internal Funding Opportunities

We will not be offering seed grants in 2019. Check back in late fall 2020/early spring 2021 for news on our next round of Team Building Grants. 


Thank you to all who applied for our 2018 Team Building Grants. We had a large number of excellent proposals, and it was difficult for the selection committee to make their decision. This year, eight teams have been selected for funding. You can find the list of recipients here. 

In 2017, we funded six grants from 3i Initiative funds, while two additional grants were funded by the Department of Pathology and the Diabetes and Metabolism Research Center. You can find a 2017 list of the awardees.


Other Funding & Award Opportunities

Funding opportunities are broken into two groups:

Click the Opportunity Number or Title to be redirected to the funding opportunity announcement.

Foundations and Other Organizations Funding Opportunities:

Foundation Grant Support: U of U Health’s Office of Advancement has an office of Foundation Relations that can help faculty with strategic approaches to private foundations. Applying for research, scholarship, and program based funding from philanthropic foundations is something all faculty should consider and pursue. Foundation Relations staff can help faculty by searching for funding opportunities, identifying foundations with ongoing initiatives in particular areas of faculty interest, providing insight about the University's current and historical relationship with foundations, reviewing proposals, and facilitating ongoing foundation relationships for faculty and their units. Faculty and staff are encouraged to reach out to Lynn Marsella Wong, Director of Foundation Relations (or through your area development officer) with any questions or to discuss an opportunity prior to approaching a funder. Lynn may be reached at 801-587-1066 or lynn.wong@hsc.utah.edu.

Organization

Title

Due Date

American Academy of Allergy, Asthma and Immunology (AAAAI)

AAAAI Foundation Faculty Development Award

November 15th

The AAAAI Foundation is dedicated to support the development of junior faculty to further their careers in Allergy and Immunology, and to help create leaders and independent investigators by funding excellent research that will lead to the prevention and cure of asthma and allergic and immunologic disease

Once the award is granted, the following requirements will need to be met to ensure that the award will continue throughout the 3-year award cycle: 
- The awardee must attend the 2020 AAAAI Annual Meeting as well as the AAAAI Foundation Benefit dinner where the awardees are announced. 
- An annual written progress report describing research efforts and other careerdevelopment aspects as well as a summary of the allocation of the received funds (Due July 1 of each award year) 
- An annual report (Due July 1 of each award year) from the awardee's mentor/chair reviewing the progress of the awardee 
- Acknowledgement of the AAAAI Foundation support when giving presentations or in any publications that result from the research conducted and sponsored by the award 

American Federation for Aging Research (AFAR)

Glenn Foundation for Medical Research and AFAR Grants for Junior Faculty

LOI: December 16th, 2019

The major goal of this program is to assist in the development of the careers of junior investigators committed to pursuing careers in the field of aging research. GMRF and AFAR support research projects concerned with understanding the basic mechanisms of aging rather than disease-specific research. Projects investigating age-related diseases are supported if approached from the point of view of how basic aging processes may lead to these outcomes. Projects concerning mechanisms underlying common geriatric functional disorders are also encouraged, as long as these include connections to fundamental problems in the biology of aging. Projects that deal strictly with clinical problems such as the diagnosis and treatment of disease, health outcomes, or the social context of aging are not eligible.

Examples of potentially fundable areas of research include, but are not limited to:

- Aging and immune function
- Stem cell aging
- Inflammation
- Genetic control of longevity
- Neurobiology and neuropathology of aging
- Invertebrate or vertebrate animal models
- Cardiovascular aging
- Aging and cellular stress response
- Metabolic and endocrine changes

Projects investigating mechanisms of, or putative therapies for, Alzheimer's Disease and related dementias, are not eligible for this award

 

 

 DEBRA International

 Chronic Inflammation and Fibrosis in EB Research Call

December 17th, 2019

DEBRA International is now inviting expressions-of-interest for research into the processes of chronic inflammation and fibrosis (CIF) in epidermolysis bullosa (EB). Research into the role of these processes and aberrant wound healing inthe initiation and spread of associated squamous cell carcinoma (SCC) in EB is also welcome. 

Non-healing wounds leading to inflammation and fibrosis are interlinked consequences of EB, posing a major burden on patient quality of life, and inturn contributing to further complications including squamous cell carcinoma. 

Greater understanding of the permissive environment of the altered extracellular matrix in EB coupled with modified interactions of proteins mutatedin EB may provide novel targets for intervention to prevent, or slow, these processes. Through this call for research proposals, DEBRA wishes to support focused research to identify treatment targets, and to expedite development of effective preventative and therapeutic approaches. 

The scope of eligible projects includes: 

- Research to develop a better understanding of the interplay of the processes of inflammation and fibrosis in chronic wounds specifically in EB, with the ultimate goal of treatments to prevent or slow these processes, and progression to SCC. 
- Clinical studies or clinical trials of therapies targeting chronic inflammation or fibrosis, or SCC initiation in any type of EB. 

The focus of the call is on chronic inflammation and fibrosis in EB, for the purpose of identifying possible targets for treatment or prevention, and preventing the initiation or spread of associated squamous cell carcinoma. Development of therapies that would address the underlying genetic defect, or established agents/methods that are used to treat squamous cell carcinoma fall outwith the scope of this call. 
World Health Organization (WHO)
Global Polio Eradication Initiative (GPEI)

 Polio Research Committee Call for Research Proposals (Collaborative Research Project)

March 24th, 2020 

The Polio Research Committee is calling for research proposals supporting the Polio Endgame Strategy 2019-2023. Research proposals supporting the strategic plan may be submitted to the Committee for review and funding. 

The current priority of the Polio Research Committee is to generate new data or information in the following areas: 

1. Vaccine schedule immunogenicity 
- Immunogenicity of poliovirus vaccination options after withdrawal of all oral poliovirus vaccines 

2. Surveillance 
- Assessment of length of poliovirus environmental circulation after withdrawal of all oral poliovirus vaccines 
- Development and evaluation of new methods for poliovirus surveillance inareas with poor access 

3. Product development 
- Development and evaluation of innovative IPV formulations or administration techniques (new mucosal adjuvants, virus-like particle [VLPs] vaccine, IPV patches, etc.) 

4. Epidemiology/virology 
- Evaluation of factors favouring emergence of vaccine derived polioviruses 

5. Monitoring & evaluation 
- Development and evaluation of new methods for assessment of quality (& coverage) of polio vaccination mass campaigns 

6. Basic immunology 
- Assessment of length of priming following IPV administration 

7. Containment 
- Research supporting containment objectives and policies 

 

 Almirall Share

Immune-inflammatory diseases under your skin 

October 31st 

We are looking for partners to help us to identify, validate or test new targets for the treatment of chronic immune-inflammatory diseases of the skin.

Psoriasis, atopic dermatitis or pemphigus vulgaris are examples of chronic immune-inflammatory skin diseases associated with significant comorbidities that have a profound impact in the quality of life of patients. They are our focus.

Many chronic immune-inflammatory diseases, irrespective of the organ affected (joints, CNS, gut or skin), share common mechanisms, pathways and players: psoriasis has therapies in common with multiple sclerosis and rheumatoid arthritis; atopic dermatitis with asthma; pemphigus with lupus, to name a few.

Regardless of your field of expertise, if you are a scientist with an idea (target, pathway, therapy) that you think might be of use in a dermatological disease, share it with us and we will explore it, together. 

Human Vaccines Project

Michelson Prizes

Pre-Application: October 31st; 2019

Application: February 4th, 2020

The Michelson Prizes are scientific awards of $150,000 given annually to young investigators who are applying disruptive research concepts and inventive processes to advance vaccine and immunotherapy research for major global diseases. 

The 2019 Michelson Prizes have been expanded to include three focus areas: Human Immunology, Computational Biology and Protein Engineering, and Neglected Parasitic Diseases. All focus areas are aimed at supporting research with the potential to transform vaccine and immunotherapy discovery. 

The Human Immunology focus area is aimed at research tackling the current roadblocks that exist in human vaccine development and expanding our limited understanding of key immune processes that are fundamental to successful vaccine and immunotherapeutics development, (e.g., immune memory, immune receptor recognition, tissue-specific responses, host-microbe interactions, underlying genetic mechanisms, genetic susceptibility, etc.). 

The Computational Biology and Protein Engineering focus area targets research that utilizes bioinformatics, theoretical methods, mathematical modeling, machine learning and/or computational approaches to elucidate protein structures involved in immune recognition, immunogenicity, protein-ligand interactions, or other biological functions related to the human immune response. Other areas of research that will be considered for funding include protein design studies with the intent of generating novel structures and/or function for the development of antigens or adjuvants, and/or for modulating or targeting host proteins to elicit increased or more specific immune response(s). 

The Neglected Parasitic Diseases focus area is aimed at research on antigen discovery, immune response mechanisms, and the development and testing of vaccines and immunotherapeutic agents for neglected parasitic diseases. This award is designed to foster research of human parasitic diseases that traditionally have been difficult to study due to antigen complexity and multifaceted host-parasite interactions. NB: This award will not fund malaria research. 

A rigorous and competitive global search will identify the most innovative projects from young scientists across a broad spectrum of scientific fields

Cancer Research Institute

Clinic and Laboratory Integration Program

LOI: November 1st, 2019

The Cancer Research Institute established Clinic and Laboratory Integration Program to support investigators who are studying critical topics at the intersection of laboratory and clinical research in immuno-oncology. CLIP grants provide up to $200,000 over a two-year period. 

CRI has obtained designated funding that will provide for a limited number of additional CLIP grants focused on topics related to biomarkers, including such topics as tumor mutational burden, microbiome, host genomic factors, and others. Proposals in this area are encouraged.

Crohn's and Colitis Foundation

Litwin IBD Pioneers Initiative

November 5th (Annually) 

The Litwin IBD Pioneers initiative, formerly known as the Broad Medical Research Program at the Crohn’s & Colitis Foundation, supports innovative clinical and translational research projects with the potential to impact the treatment of IBD patients in the near future. The program encourages novel research into the diagnosis, identification of clinically relevant subsets, treatments, and cures for inflammatory bowel diseases (IBD) and funds innovative pilot research so that scientists can test their initial ideas and generate preliminary data. View previously funded grants.

Litwin IBD Pioneers supports researchers who are exploring all possible opportunities for diagnostic and therapeutic improvements, including novel, out-of-the-box ideas, and funds innovative and pioneering ideas that have a clinically relevant focus. Additionally, the program is open to investigators from other disciplines new to the IBD field, as well as countries outside the United States.

Crohn's and Colitis Foundation

Career Development Awards

November 5th (Annually) 

Career Development Awards are mentored awards intended to facilitate the development of individuals with research potential to prepare for a career of independent basic and/or clinical investigation in the area of inflammatory bowel disease (IBD).

Crohn's and Colitis Foundation

Senior Research Awards

November 5th (Annually) 

 To provide established researchers with funds to generate sufficient preliminary data to become competitive for funds from other sources such as the National Institutes of Health (NIH).

ISDA Foundation

Alzheimer's and Infectious Diseases Research Grant

November 30th, 2019

The IDSA Foundation is excited to announce the availability of up to five (5) $100,000 grant awards for investigators interested in research explicitly directed toward whether an infectious agent or microbial mechanism is responsible for triggering or driving Alzheimer’s Disease. These awards will provide seed funding to encourage innovative projects that will lead investigators to initiate promising new directions in Alzheimer’s-related research that may enable them to compete successfully for national research grants. Targeted projects may rest in basic, translational, epidemiologic, or clinical research that seeks to answer fundamental questions about whether an infectious factor or process leads to the development and progression of Alzheimer’s disease.

Thrasher Research Fund

E.W. "AI" Thrasher Awards

Ongoing Dates

The Thrasher Research Fund has been awarding grants for children's medical research for over 40 years. The purpose of the E.W. "Al" Thrasher Awards is to improve children's health through medical research, with an emphasis on projects that have the potential to translate into clinically meaningful results within a few years. The Fund awards grants two times per year, with no fixed number of awards given in each funding cycle or in each year.

Bay Area Lyme Foundation

Scientific Grants

Ongoing

Bay Area Lyme Foundation accepts grant proposals on a rolling basis year round. We accept applications from universities, hospitals, and independent research entities all over the United States.

Awardees are evaluated on their concepts, ideas, methods, and resourcefulness in bringing new vision into the field of Lyme disease research. Our mission is to fund research and development of novel diagnostics and treatments for Lyme disease.

Grant recipients do not need to have previous experience in Lyme disease research. Every year, we fund researchers who, while respected in their scientific areas of focus, have never previously leveraged their knowledge and abilities for research in Lyme disease.

Alzheimer's Drug Discovery Foundation

Core Requests For Proposals

Ongoing

The Alzheimer's Drug Discovery Foundation currently has four core request programs available with rolling deadlines:

  1. Program to Accelerate Clinical Trials

  2. Biomarkers Development

  3. Prevention Beyond the Pipeline

  4. Drug Discovery

Immune Tolerance Network

Clinical Trials or Assay and Biomarker Proposals

Ongoing

Clinical Trials: The Immune Tolerance Network (ITN) accepts applications for novel clinical trials from all interested scientists from academia, industry and government, in the areas of:

  • Allergy & Asthma

  • Autoimmune Diseases

  • Kidney & Liver Transplantation

Assays & Biomarkers: In addition, the ITN accepts applications for the development of novel tolerance assays or mechanistic studies for the purposes of establishing new surrogate markers of immune tolerance and investigating the mechanisms of clinical tolerance. For example, the ITN will consider proposals that seek to better understand clinical tolerance by utilizing ITN tolerance assay resources in existing or planned clinical trials that are funded through other sources.

The ITN does NOT accept proposals for non-human or preclinical studies.

Guthy-Jackson Charitable Foundation

Neuromyelitis Optica Spectrum Disorder Grants 

Ongoing

The Guthy-Jackson Charitable Foundation (GJCF) is committed to enhancing the scientific and clinical knowledge base by supporting innovative research to accelerate solutions for NMOSD. Funding priorities are those that advance understanding of the pathophysiology and immunology of this disease in a manner that enables translation to clinical benefit and betterment of the NMOSD patient community.

The Campbell Foundation

AIDS Research Grant

Ongoing

The Campbell Foundation in Fort Lauderdale, Fla. is committed to funding novel and groundbreaking laboratory-based HIV and AIDS research

Jeffrey Modell Foundation

C.H.I.L.D.R.E.N!

Ongoing

To alleviate disease, seek cures, and ultimately improve the quality of life of children affected with Primary Immunodeficiency throughout the world. The focus of this grant program is to investigate immunological disorders, control of infectious disease, and initiatives to decrease infant mortality. Additionally, the Jeffrey Modell Foundation encourages applicants to strongly consider addressing healthcare disparities, especially in developing countries, through education, testing, diagnosis, and treatment. 

Jeffrey Modell Foundation

Specific Defect Research

Ongoing

The goal of the Specific Defect Research Program is to support research to study the mechanisms and presentation of specific defects of the immune system, leading to a better understanding of the conditions and their impact on overall health outcomes. The Jeffrey Modell Foundation database includes high numbers of various genotypes around the world. This database can provide an excellent platform for collaboration. This can evolve into sharing patient samples and setting up international collaborative studies. Working together with the Jeffrey Modell Foundation, investigators will have access to this international database and be able to contact other sites in order to coordinate studies.

Jeffrey Modell Foundation

Translational Research

Ongoing

It is estimated that as many as 10 million people, if not more, are living with Primary Immunodeficiency worldwide. Over the past decade, identification and diagnosis of Primary Immunodeficiency has greatly expanded, and knowledge of causative genes continues to rapidly grow. Simultaneously, genomics technology is becoming more readily available and cost-effective. The time is crucial to support research that will bridge basic science discoveries to the development of clinical applications that will impact overall health outcomes. Advancing the understanding of the mechanisms of Primary Immunodeficiency diseases has the ability to provide essential knowledge of immune function. Harnessing the power of understanding the immune system represents one of the single greatest disease-fighting and life-saving strategies that biomedical science has to offer and will greatly benefit those with identified Primary Immunodeficiencies, and the millions that remain undiagnosed.

 National Multiple Sclerosis Society

Multiple Opportunities

Ongoing

The National Multiple Sclerosis Society welcome applications for studies related to multiple sclerosis that may serve to advance our mission of stopping MS progression, restoring function and improving quality of life, and preventing MS. The Society supports fundamental as well as applied studies, non-clinical or clinical in nature, including projects in patient management, care and rehabilitation.

 Abbvie

Advancing Science through Investigator-led Research

Ongoing

The research from investigator-initiated studies may expand our understanding of our products and their potential applications. Plus, it may improve patient care and spark new ideas for further disease-related research.

The AbbVie IIS Program provides an opportunity to academic and community-based physicians and researchers worldwide interested in conducting their own research to apply for research support.

Visit the IIS Submission Portal to learn more or to apply.

Merck

Investigator Studies Program (MISP)  Ongoing

The Company Investigator Studies Program is open to all academic and community-based physicians and researchers worldwide who are interested in conducting their own research. This program consists of committees of medical and scientific staff from different therapeutic areas who meet regularly to review our company's investigator study proposals. Support is provided based on the scientific merit of the proposal as well as whether it is in alignment with the published areas of interest. Information related to areas of interest and requirements for submission can be found by clicking on the appropriate link for your therapeutic area.

 Submission of a proposal does not imply or guarantee approval. All proposals will be reviewed based on research merit criteria. Financial and/or product support is contingent upon full execution by both parties of the research agreement.

Federal Funding Opportunities

Opportunity Number Agency Title Due Date

PAR-19-198 (R01) &

PAR-19-199 (R21)

National Cancer Institute (NCI)

Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer

November 6, 2019

June 10, 2020

November 6, 2020

June 10, 2021

November 8, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses.  Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation.  

18-581 

National Science Foundation

Ecology and Evolution of Infectious Diseases  (EEID)

November 20, 2019

The multi-agency Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, and social principles and processes that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of transmission among humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of reservoir species or hosts; the feedback between ecological transmission and evolutionary dynamics; and the cultural, social, behavioral, and economic dimensions of pathogen transmission. Research may be on zoonotic, environmentally-borne, vector-borne, or enteric pathogens of either terrestrial or freshwater systems and organisms, including diseases of animals and plants, at any scale from specific pathogens to inclusive environmental systems. Proposals for research on disease systems of public health concern to developing countries are strongly encouraged, as are disease systems of concern in agricultural systems. Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, modelers, ecologists, bioinformaticians, genomics researchers, social scientists, economists, epidemiologists, evolutionary biologists, entomologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases.

PAR-18-333

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Allergy and Infectious Diseases (NIAID)

Understanding the Early Development of the Immune System

December 5, 2019

The purpose of this funding opportunity announcement (FOA) is to support studies on the very early development of the immune system and the humoral and cellular communication that exists between the mother and fetus that may shape or impact immune system development and maturation.  

PAR-16-254 (R01) & 

PAR-18-923 (R21)

 National Institute of Allergy and Infectious Diseases (NIAID)

Characterization of Mycobacterial Induced Immunity in HIV-infected and Uninfected Individuals 

 January 14th, 2020

January 14th, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative studies to identify and understand the immunological responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected or uninfected individuals. Development of novel functional assays to assess host response and inclusion of immune profiling and systems biology approaches are encouraged.

This FOA seeks to stimulate innovative research in deciphering immune mechanisms in humans required for protection from Mtb infection or tuberculosis (TB) disease, or induced by TB vaccines, that go beyond what have traditionally been investigated in TB.    

PAR-19-307 (R01) &

PAR-18-923 (R21)

National Institute of Allergy and Infectious Diseases (NIAID) Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design

 January 14th, 2020

January 14th, 2021

January 14th, 2022

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative studies to identify and understand the immune responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or progression to active tuberculosis (TB) disease. Such responses may be operative in mycobacterial infection, or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational TB vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected and/or uninfected individuals. Research supported under this FOA should go beyond descriptive information currently known about Mtb infection, immune responses to TB vaccines, or immune modulation by non-tuberculous mycobacterial (NTM) infection, or by HIV/AIDS. Applications are sought that include characterization of the timing, anatomical location, and contribution to disease outcome, of mucosal and/or systemic immune responses to mycobacterial infection and/or vaccination. This research is expected to advance understanding of immune mechanisms in Mtb infection/vaccination and contribute to the advancement of new TB vaccines, including in populations also infected with HIV.

PAR-18-860

National Institute of Allergy and Infectious Diseases (NIAID)

Immune Response to Arthropod Blood Feeding

February 14th, 2020

October 15th, 2020

The purpose of this Funding Opportunity Announcement (FOA) is to support short-term exploratory, developmental, and transdisciplinary research to understand the immunologic events that occur during blood feeding by hematophagous arthropods.  The scientific objectives of this initiative are (1) to understand the immunological events in the vertebrate host, which occur during and after blood feeding by hematophagous arthropods, at the bite site (skin) and systemically; (2) to identify and characterize the immune modulatory properties of arthropod salivary components; and (3) to understand the immunological events in the hematophagous arthropods following a blood meal.

PAR-18-830

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Cancer Institute (NCI)


National Eye Institute (NEI)

The Role of Epitranscriptomics in Development and Disease (R01 - Clinical Trial Not Allowed)

March 3rd 2020;

November 7th, 2020;

June 3rd, 2021;

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of epitranscriptomics, i.e., the chemical modifications of RNA.  Evidence is accumulating that RNA modifications regulate the function of both coding and noncoding RNAs, suggesting that these modifications are involved in both development, and in health and disease.  Yet the extent and types of these RNA modifications as well as their roles in particular biological processes remain either poorly understood or not known.  The goal of the FOA is to promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
PAR-18-831

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Cancer Institute (NCI)


National Eye Institute (NEI)

The Role of Epitranscriptomics in Development and Disease (R21 - Clinical Trial Not Allowed)

March 3rd 2020;

November 7th, 2020;

June 3rd, 2021;

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area ofepitranscriptomics, i.e., the chemical modifications of RNA.  Evidence is accumulating that RNA modifications regulate the function of both coding and noncoding RNAs, suggesting that these modifications are involved in both development, and in health and disease.  Yet the extent and types of these RNA modifications as well as their roles in particular biological processes remain either poorly understood or not known.  The goal of the FOA is to promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). 

PAR-19-247 (R21)

PAR-19-248 (R01) 

National Institute of Allergy and Infectious Diseases (NIAID) Research Projects to Improve the Predictive Value of Animal Models in Recapitulating Human Immunity to Influenza Infection and Vaccination

June 10th/18th, 2020

June 10th/18th, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to support research to improve existing animal models or develop novel animal models that more accurately represent influenza immunity in humans, with an emphasis on increasing the predictive value of models for evaluating novel universal influenza vaccines.
PAR-18-781 National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory Mechanisms (R21 Clinical Trial Not Allowed)

September 9, 2020

The purpose of this Funding Opportunity Announcement (FOA) is to support the use of Collaborative Cross (CC) mouse lines to advance understanding of the host genetics involved in immune regulation and function and to further develop CC mouse lines that more faithfully reproduce human immune responses. Applicants may include CC, CC derivatives with reproducible genomes and/or CC-RIX mice to accomplish these goals. Research areas supported by this FOA include immune system development, function or regulation; mechanisms governing immune response to infectious pathogens, vaccines or adjuvants; host susceptibility factors and mechanisms of pathogen-induced immunopathology; and immune mechanisms involved in the development and progression of immune-mediated diseases, such as allergy/asthma, autoimmunity, primary immunodeficiency, inflammation, and cell/organ/tissue transplant rejection or tolerance.
RFA-DK-19-008 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Adipogenesis, Adipocyte Function and Obesity Following HIV Infection, Antiretroviral Therapy, or Pre-Exposure Prophylaxis (R01 Clinical Trial Optional) November 7, 2019
The prevalence of obesity is increasing in people with HIV (PWH), contributing to multiple complications associated with this condition. There is mounting evidence that unique mechanisms contribute to the development of obesity in PWH versus people without HIV. Alterations in fat tissue biology may be central to these differences. This FOA seeks applications to elucidate the underlying mechanisms of how HIV and antiretroviral drugs used for therapy or pre-exposure prophylaxis contribute to the development of obesity and alter adipocyte and adipose tissue function as well as the effects of these processes on metabolic and physiological processes within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
PA-18-838 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R01 Clinical Trial Optional) Standard Dates
The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research related to the role of the gut microbiome in regulating metabolism and reproduction, and its impact on fertility status. The overarching goal is to gain fundamental insight into the possible role of the gut microbiome in regulating reproduction through hypothalamo-pituitary-gonadal (HPG), hypothalamo-pituitary-adrenal (HPA), and hypothalamo-pituitary-thyroid (HPT) axes in the brain. The results of the study could lead to development of diagnostic markers (signature microbiomes) for reproductive and metabolic failure. The project is pertinent to multiple portfolios in the Fertility and Infertility Branch, e.g., basic ovarian biology, fertility preservation, assisted reproductive technology, spermatogenesis and sperm function, and therapeutic interventions to infertility. The emphasis on the gut microbiome and its impact on reproduction through its effects on HPG, HPA, and HPT axes leading to obesity, metabolic syndrome, stress disorders, infection and anxiety is also of interest to the Maternal and Pediatric infectious disease Branch, Pediatric Growth and Nutrition Branch and Intellectual and Developmental Disabilities Branch.
PAR-18-725 National Institute of Allergy and Infectious Diseases (NIAID) Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R01 Clinical Trial Not Allowed) Standard Dates
The purpose of this Funding Opportunity Announcement (FOA) is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance.
PAR-18-724 National Institute of Allergy and Infectious Diseases (NIAID) Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R21 Clinical Trial Not Allowed) Standard Dates
The purpose of this Funding Opportunity Announcement (FOA) is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance.

Veteran's Affairs

Research Grants

A variety of mechanisms are available, please see website for details. 

 PAR-18-712

National Institute of Allergy and Infectious Diseases (NIAID) Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R01 Clinical Trial Not Allowed) Standard NIH Dates
The purpose of this Funding Opportunity Announcement (FOA) is to advance the discovery and characterization of primary immunodeficiency diseases, also referred to as inborn errors of immunity, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders.
National Institute of Allergy and Infectious Diseases (NIAID)
Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R01 Clinical Trial Optional)
Standard NIH Dates

The overall purpose of this funding opportunity announcement (FOA) is to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as related to health and disease. This FOA will support basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science.

PA-18-739 National Institute of Allergy and Infectious Diseases (NIAID) Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R21 Clinical Trial Optional) Standard NIH Dates
The overall purpose of this funding opportunity announcement (FOA) is to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as related to health and disease. This FOA will support basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science.
PA-18-784 National Heart, Lung, and Blood Institute (NHLBI) The Mechanistic Role of the Microbiome in the Pathobiology of Heart, Lung, Blood, and Sleep Diseases (R01 - Clinical Trial Not Allowed) Standard NIH Dates
The purpose of this funding opportunity announcement (FOA) is to support functional microbiome research focused on understanding the molecular, immunological and physiological mechanisms by which the microbiota (gut, lung, oral, including bacteria, viral and fungal microflora) and its derived factors modulate heart, lung, blood and sleep (HLBS) biology and physiology to promote health or contribute to disease. This FOA encourages mechanistic studies using in vitro, in vivo and/or ex vivo models that focus on the mechanistic and functional involvement of the microbiome and their components in the modulation or activation of host pathways. The goal is to provide the critical knowledge to guide early translational approaches for better understanding and treatment of HLBS conditions in adults and children. This FOA encourages multidisciplinary collaborations among scientists in a wide range of disciplines including (but not limited to) cardiology, pulmonology, hematology, sleep science, circadian biology, immunology, '-omic' sciences, microbiology, microbial ecology, biotechnology, and bioinformatics.
PA-18-902 National Cancer Institute (NCI)
National Center for Complementary and Integrative Health (NCCIH)
Office of Dietary Supplements (ODS)
Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional) Standard NIH Dates

The purpose of this funding opportunity announcement (FOA) is twofold: 1). to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2). to understand the underlying mechanisms of their action(s), and variability in responses to these interventions.

This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies.

PA-19-049 National Heart, Lung, and Blood Institute (NHLBI) New Research Directions that Advance the NHLBI Strategic Vision Normal Biology (R21 - Clinical Trial Not Allowed) Standard NIH Dates
The development of more effective means for diagnosing and treating heart, lung, blood, and sleep (HLBS) disorders is often aided by a detailed understanding of normal biology, specifically the nature and operations of the molecular systems and cells that are affected by those diseases. Areas of research interest include studies of fundamental processes that explain “resilience” – the capability of some individuals to maintain or restore normal function despite aging or exposure that causes disease in others. This Funding Opportunity Announcement (FOA) will support pilot studies by R01-funded investigators in areas of research that advance high priority studies of normal biology and resilience as described by Objective 1 of the NHLBI Strategic Vision.  

PA-19-042 (R01) and 

PA-19-050 (R21)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Mental Health (NIMH)

Engaging Men in HIV Testing, Prevention, and Care Standard NIH Dates

The purpose of this Funding Opportunity Announcement (FOA) is to develop and test strategies to increase the engagement of men in HIV prevention and care within global settings and among US domestic populations who have evidenced lower rates of engagement and retention in HIV prevention and care.

The R01 mechanism is intended to support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.

The R21 Exploratory/Developmental Grant supports studies that may involve considerable risk but may lead to a breakthrough in a particular area; or to the development of novel techniques, agents, methodologies, models; or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

 

PA-19-020 National Institute of Allergy and Infectious Diseases (NIAID) Fc-Dependent Mechanisms of Antibody-Mediated Killing (R21 Clinical Trial Not Allowed) Standard NIH Dates
This Funding Opportunity Announcement (FOA) invites applications for studies that address knowledge gaps in mechanisms of Fc-dependent, antibody-mediated killing of infected cells or aberrant cells, or antibody-mediated therapeutic ablation of cells implicated in immune pathologies, including autoimmune and allergic diseases. More specifically, the purpose of this FOA is to promote innovative and exploratory research to elucidate mechanisms of antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP), and to promote development of tools, technologies, and animal models to facilitate identification and evaluation of cytotoxic killing mechanisms mediated by human antibodies in vivo. This FOA uses the R21 grant mechanism, while the companion FOA, RFA- AI-18-042, uses the U01 mechanism. Applicants with preliminary data and/or planning longer-term studies may wish to apply using the U01 mechanism.
PA-19-068 National Institute of Allergy and Infectious Diseases (NIAID) Secondary Analysis of Existing Datasets for Advancing Infectious Disease Research (R21 Clinical Trial Not Allowed) Standard Dates
The purpose of this Funding Opportunity Announcement (FOA) is to support projects that utilize open-access data, alone or in combination with other datasets, to address knowledge gaps in basic and/or clinical research in infectious diseases.  

PAR-19-078 (R01) &

PAR-19-079 (R21)

National Institute of Allergy and Infectious Diseases (NIAID) Molecular and Genetic Characterization of Inborn Errors of Immunity  Standard Dates

The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics.       

PA-19-067 &

PA-19-066

National Institute of Allergy and Infectious Diseases (NIAID) Processing and Presentation of Non-Conventional MHC Ligands (R01 & R21) Standard Dates
This Funding Opportunity Announcement (FOA) invites applications to characterize antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands presented by classical and non-classical MHC class I and class II molecules, and to determine the contribution of these unique antigenic ligands to: protective immune responses to infectious pathogens and/or vaccines; pathogen-associated immune pathogenesis; and/or in the induction/progression or prevention of immune-mediated diseases. These studies may facilitate the development of novel tools and reagents to advance design of immune-based therapeutics and vaccines.

PA-19-082 (R01)

PA-19-083 (R21)

National Institute of Allergy and Infectious Diseases (NIAID) Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis (Valley Fever) and other select endemic fungal infections Standard Dates
The purpose of this Funding Opportunity Announcement is to support research activities that will contribute to the overall understanding of coccidioidomycosis, commonly known as Valley Fever, and other select endemic fungal diseases including histoplasmosis and blastomycosis.  This research opportunity encourages studies that address diverse scientific areas such as: 1) pathogenesis; 2) host response; 3) disease transmission; 4) natural history and environmental factors contributing to disease; 5) vaccines; 6) diagnostics; and 7) therapeutics; with the ultimate goal of advancing the field towards solutions for the improved detection, prevention and treatment of select endemic mycoses.

PA-19-080 (R01)

PA-19-081 (R21)

National Institute of Allergy and Infectious Diseases (NIAID) Advancing Development of Rapid Fungal Diagnostics Standard Dates
The purpose of this Funding Opportunity Announcement is to support the development of rapid, sensitive, specific, simple, and cost-effective diagnostics for primary health-care settings (hospitals and point-of-care).
PA-19-077 National Institute of Allergy and Infectious Diseases (NIAID) Accelerating Malaria Vaccine Discovery (R01 Clinical Trial Not Allowed) Standard Dates
The purpose of this Funding Opportunity Announcement (FOA) is to support early phase translational research that will generate new malaria vaccine candidates suitable for further downstream development and clinical evaluation.  This research opportunity encourages studies that will lead to discovery of new vaccine candidates that prevent infection, ameliorate disease, and/or interrupt transmission caused by human malaria parasites, especially P. falciparum and P. vivax.
PA-19-096 National Institute of Allergy and Infectious Diseases (NIAID) Control of Sexually Transmitted Infections (STIs) Through a Comprehensive Understanding of the Natural History of Infection  Standard Dates
The purpose of this Funding Opportunity Announcement (FOA) is to encourage research to advance the understanding of natural history of infection for three sexually transmitted infections (STIs): gonorrhea, syphilis, and chlamydia. This research opportunity encourages studies that address the natural history of infection in the context of either: 1) correlates of protection, 2) host response to infection, 3) clinical endpoints of disease, or 4) biological and clinical factors that influence clearance rather than persistence of infection.
PAS-19-097 National Institute of Allergy and Infectious Diseases (NIAID) Research to Advance HBV Cure: HIV/HBV Co-Infection and HBV Mono-infection (R01 Clinical Trial Not Allowed) Standard Dates
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative basic, translational, and clinical research to identify and address the challenges to achieving hepatitis B virus (HBV) cure in the presence or absence of human immunodeficiency virus (HIV).
PAS-19-105 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute on Aging (NIA)
Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed) Standard Dates
The Stimulating Hematology Investigation:  New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI).  Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain.  Specific emerging topics that are at the leading edge of the field will change over time and will be updated annually through the NIH Guide to Grants and Contracts and hyperlinked to this FOA. 
PAR-19-155 National Heart, Lung, and Blood Institute (NHLBI) NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional) Standard Dates
This Funding Opportunity Announcement (FOA) is to support studies that are scientifically essential, yet also sufficient, for investigators to make definitive decisions that inform the final designs of important Phase II and beyond clinical trials within NHLBI's mission; that is, clinical trials with the primary intent of testing the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and treatment of heart, lung, blood, and sleep disorders. This mechanism may be used to test the feasibility of novel and efficient (pragmatic) trial designs, as well as determine the feasibility of an intervention, intervention parameters, subject availability, or other information essential to complete the design of a trial. Applications should demonstrate that the proposed studies are both necessary and sufficient to permit definitive decisions about the final design of the subsequent clinical trial. Applicants who propose solely to write a protocol or manual of operations, to develop infrastructure for a clinical trial, or implement a fully designed trial will not be considered appropriate for this announcement. Please note that NHLBI supports other funding opportunities for clinical trials-see https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization for information on other NHLBI clinical trial funding opportunity announcements. In contrast to the planning or study start up phase of other NHLBI clinical trial FOAs, the R34 mechanism is intended to provide new information that answers a scientific question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial.

PAR-19-172(R01)

PAR-19-173(R21)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R01& R21 Clinical Trial Not Allowed) Standard Dates
This funding opportunity announcement (FOA) encourages state-of-the-art, systematic research approaches to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial (DOC) diseases. This FOA encourages applications that will seek to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward regeneration disease management in a patient-specific manner across the lifespan.
PA-19-237 National Institute of Allergy and Infectious Diseases (NIAID) Novel RNAs in Virology (including HIV) and Immune Regulation: Basic Science and Therapeutic Discovery (R21 Clinical Trial Not Allowed) Standard Dates
The purpose of this Funding Opportunity Announcement (FOA) is to support basic science research, from early exploratory studies to therapeutic discovery and development, in novel biologically active viral and/or host RNAs involved in virology (including HIV biology) and immune regulation.

PAR-16-228 (R01)

PAR-16-229 (R21)

National Cancer Institute (NCI) Metabolic Reprogramming to Improve Immunotherapy Standard Dates
The overall goal of this funding opportunity announcement (FOA)  is to encourage R01 grant applications to (a) generate a mechanistic understanding of the metabolic processes that support robust anti-tumor immune responses in vivo, (b) determine how the metabolic landscape of the tumor microenvironment affects immune effector functions, and (c) then use this information to manipulate (reprogram) the metabolic pathways used by the tumor, the immune response, or both to improve cancer immunotherapy.
PA-18-724 National Institute of Allergy and Infectious Diseases (NIAID) Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R21 Clinical Trial Not Allowed) Standard Dates
The purpose of this Funding Opportunity Announcement (FOA) is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance.

PA-18-031(R01) &

PA-18-092 (R21)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Advancing Understanding, Prevention, and Management of Infections Transmitted from Women to their Infants  Standard Dates
The purpose of this funding opportunity announcement (FOA) is to stimulate investigations including translational, epidemiologic and clinical studies and trials that improve the understanding, prevention and clinical outcomes of non-HIV infections transmitted from women to their offspring during pregnancy, labor and delivery, and breastfeeding. NICHD is committed to supporting research that will increase scientific understanding of and treatments for high-priority perinatal infections.

PAR-19-193 (R01) & 

PAR-19-194 (R21)

National Cancer Institute (NCI)
National Institute on Dental and Craniofacial Research ( NIDCR )
Microbial-based Cancer Therapy -Bugs as Drugs Standard Dates

The overall purpose of this funding opportunity announcement (FOA) is to stimulate the development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaebacteria, bacteriophages and other non-virus microorganisms, this initiative will support research projects designed to study the underlying mechanisms of the complex interactions between microorganisms, tumor, and immune system. The FOA also aims to support research into the use of microorganisms as delivery vehicles for cancer treatment and to complement or synergize with current therapies.  This FOA will accept basic mechanistic and preclinical studies in cell culture and animal models in accordance with the state of the science. Applicants applying to this FOA are encouraged to address both the microbial and the tumor aspects of microbial-based cancer therapy.

Complex microbial-tumor interactions are best addressed with a team approach. The purpose of this FOA is to encourage basic or applied, multidisciplinary research collaborations between investigators from areas relevant to microbial-based cancer therapy, such as microbiology, oncology, immunology, and cellular and molecular cancer biology. The proposed projects should be state of the art and aim to advance pre-clinical development of novel microbial-based anticancer therapeutic agents, or study the complex biology involved in the interplay of microbe-tumor-immune system. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research, and should apply an integrative approach to increase our understanding of biological, or translational aspects of microbial-based anticancer therapeutic agents.

PAR-17-438

National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute on Deafness and Other Communication Disorders (NIDCD)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)
Assay development and screening for discovery of chemical probes or therapeutic agents (R01) Standard Dates

Through this funding opportunity announcement (FOA), NIH wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes; and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets.

Stages of discovery research covered by this FOA include: 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.

PA-17-008 (R01) & 

PA-17-007 (R18)

Agency for Healthcare Research and Quality (AHRQ)

Center for Quality Improvement and Patient Safety (CQuIPS)  

Large Research Projects for Prevention of Healthcare-Associated Infections Standard Dates

 This FOA issued by AHRQ invites grant applications for funding to conduct Large Research Projects (R01) that propose to advance the base of knowledge for detection, prevention, and reduction of Healthcare-Associated Infections (HAIs). The FOA describes the broad areas of HAI research for which funds are available to support Large Research Projects  

PA-17-114

National Institute of Allergy and Infectious Diseases (NIAID) NK Cells to Induce Immunological Memory to Prevent HIV Infection  Standard Dates

The purpose of this Funding Opportunity Announcement (FOA) is to support multidisciplinary, hypothesis-driven research on Natural Killer (NK) cells, leading to the discovery of pathways relevant for early immune responses and immune regulation impacting the potential protective immunity to be induced by HIV vaccination. Secondary objectives include the development of novel technologies to allow for more definitive studies of human immune monitoring in the context of vaccine clinical trials and the recruitment of innate immunologists to the HIV vaccine field.

PA-17-008 (R01) &

PA-17-007 (R18)

Agency for Healthcare Research and Quality (AHRQ)

Center for Quality Improvement and Patient Safety (CQuIPS)  

Large Research Projects for Prevention of Healthcare-Associated Infections Standard Dates

 This FOA issued by AHRQ invites grant applications for funding to conduct Large Research Projects that propose to advance the base of knowledge for detection, prevention, and reduction of Healthcare-Associated Infections (HAIs). The FOA describes the broad areas of HAI research for which funds are available to support Large Research Projects